Curated News
By: NewsRamp Editorial Staff
June 01, 2026

Helus Pharma CEO to Speak at Jefferies Global Healthcare Conference

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Helus Pharma's CEO fireside chat at Jefferies conference could boost investor interest and stock visibility.
  • Helus Pharma develops novel serotonergic agonists, with HLP003 in Phase 3 for major depressive disorder.
  • Helus Pharma's NSAs aim to treat depression and anxiety, offering hope for durable mental health improvements.
  • Helus Pharma's HLP003 has FDA Breakthrough Therapy Designation for major depressive disorder adjunctive treatment.

Impact - Why it Matters

This news matters because Helus Pharma is advancing novel treatments for major depressive disorder and generalized anxiety disorder, conditions affecting millions globally. The company's Breakthrough Therapy Designation for HLP003 signals potential for faster regulatory review and market access, which could provide new options for patients with treatment-resistant depression. The Jefferies conference fireside chat offers investors and stakeholders insight into the company's strategic direction and clinical progress.

Summary

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The discussion, scheduled for 2:35 p.m. EDT, will be webcast live, with a replay available via the company’s investor relations website. Helus Pharma, the commercial operating name of Cybin Inc., is focused on addressing unmet needs in mental health by developing proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity.

The company is advancing two key candidates: HLP003, a proprietary NSA in Phase 3 clinical development for adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. FDA; and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland, and provides updates on its website and social media channels.

For investors, the latest updates on HELP are available in the company’s newsroom at IBN. The press release was disseminated on behalf of Helus Pharma by BioMedWire, a specialized communications platform focusing on biotech and life sciences. BioMedWire is part of IBN’s Dynamic Brand Portfolio and offers services including press distribution, editorial syndication, and social media reach. For more information, visit BioMedWire.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Speak at Jefferies Global Healthcare Conference

blockchain registration record for this content.